On Monday, Tempus AI, Inc. TEM agreed to acquire Personalis, Inc. PSNL, aiming to advance cancer monitoring through enhanced ...

ARUP Laboratories has launched the clinical CLARISPECT Multiple Myeloma MRD by Spectral Flow Cytometry assay for multiple ...

Imunon Inc. IMNN on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) ...

Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA clearance ...

We applied AVENIO targeted next-generation sequencing to plasma, tumor, and urine samples acquired on the day of curative-intent surgery from 24 prospectively enrolled patients with oligometastatic ...

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its ...

Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal Congress in Munich, Germany.

ARUP Laboratories today announced the launch of ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry. The new ...

Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets ...

Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...

Most oncologists in a recent survey said they lack the knowledge and data to use measurable, or minimal, residual disease (MRD) as a decision-making tool in the treatment of multiple myeloma. A new ...